{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:42:49Z","timestamp":1773672169920,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Valeant Pharmaceuticals North America LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Acne vulgaris (acne) is the most common skin disease we see in dermatology practice. Clinically, it is characterized by a combination of open and closed comedones (formally referred to as noninflammatory lesions) and inflammatory papules and pustules. Comedonal acne is more typical in young adolescents, but can occur in combination with inflammatory papules and pustules at any time. Topical retinoids have long been advocated for the treatment of comedonal acne.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Given the increasing recognition of the inflammatory nature of acne and the synergistic benefits seen with fixed combinations we review the latest clinical data to provide guidance on optimal management of comedonal acne.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An English language literature search of Medline, <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>, and the Web of Science using key terms (acne, comedonal, noninflammatory, clinical trials) was conducted, and relevant articles reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Comparative data is sparse, but we show the importance of fixed combinations with and without retinoids, where treatment benefits are comparable. Adapalene 0.1%\u2010benzoyl peroxide 2.5% gel has been shown to be comparable to clindamycin 1%\u2010benzoyl peroxide 5% gel, and adapalene 0.3%\u2010benzoyl peroxide 2.5% gel. A meta\u2010analysis suggested that clindamycin 1.2%\u2010benzoyl peroxide 2.5% gel was more effective than clindamycin\u2010benzoyl peroxide 5% gel in noninflammatory lesions, and two equivalent clinical programs suggest additional benefits of higher doses of benzoyl peroxide (3.75% vs 2.5%) in this fixed combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clindamycin 1.2%\u2010benzoyl peroxide 3.75% gel may afford similar benefits to adapalene 0.3%\u2010benzoyl peroxide 2.5% gel in this sometimes difficult to treat patient population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.12497","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T11:09:32Z","timestamp":1517310572000},"page":"227-231","source":"Crossref","is-referenced-by-count":12,"title":["Management of comedonal acne vulgaris with fixed\u2010combination topical therapy"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-5433","authenticated-orcid":false,"given":"Michael H","family":"Gold","sequence":"first","affiliation":[{"name":"Gold Skin Care Center Nashville TN USA"},{"name":"Tennessee Clinical Research Center Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[{"name":"The Acne Treatment and Research Center Morristown NJ USA"},{"name":"Rutgers Robert Wood Johnson Medical Center Newark NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Lin","sequence":"additional","affiliation":[{"name":"Valeant Pharmaceuticals Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.048"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680020078009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030040006"},{"key":"e_1_2_9_5_1","first-page":"708","article-title":"Post\u2010adolescent acne in women: more common and more clinical considerations","volume":"11","author":"Kim GK","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12757"},{"key":"e_1_2_9_7_1","first-page":"549","article-title":"Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris","volume":"9","author":"Tanghetti EA","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.6.726"},{"key":"e_1_2_9_9_1","first-page":"27","article-title":"The role of inflammation in the pathology of acne","volume":"699","author":"Tanghetti EA","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_9_10_1","first-page":"783","article-title":"Clinical evidence for the role of a topical anti\u2010inflammatory agent in comedonal acne: findings from a study of dapsone 0.5% gel in combination with tazarotene 0.1% cream in patients with acne vulgaris","volume":"10","author":"Tanghetti E","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_11_1","first-page":"256","article-title":"Tazarotene versus tazarotene plus clindamycin\/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double\u2010blind, randomized parallel\u2010group trial","volume":"5","author":"Tanghetti E","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_12_1","first-page":"616","article-title":"Study results of benzoyl peroxide 5%\/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris","volume":"6","author":"Del RJ","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_2_9_13_1","first-page":"9","article-title":"Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance","volume":"79","author":"Leyden JJ","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_9_14_1","first-page":"110","article-title":"A North American study of adapalene\u2010benzoyl peroxide combination gel in the treatment of acne vulgaris","volume":"84","author":"Gold LS","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09209.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.006"},{"key":"e_1_2_9_17_1","first-page":"1395","article-title":"Treatment of 2,453 acne vulgaris patients aged 12\u201017 years with the fixed\u2010dose adapalene\u2010benzoyl peroxide combination topical gel: efficacy and safety","volume":"9","author":"Eichenfield LF","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_18_1","first-page":"223","article-title":"Study of the efficacy, tolerability, and safety of 2 fixed\u2010dose combination gels in the management of acne vulgaris","volume":"84","author":"Zouboulis CC","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_9_19_1","first-page":"1427","article-title":"Customized single\u2010agent therapy management of severe inflammatory acne: a randomized, double\u2010blind, parallel\u2010group, controlled study of a new treatment \u2013 adapalene 0.3%\u2010benzoyl peroxide 2.5% gel","volume":"14","author":"Weiss J","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0178-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.040"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.03.014"},{"key":"e_1_2_9_23_1","first-page":"28","article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris","volume":"8","author":"Cook\u2010Bolden FE","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_9_24_1","first-page":"969","article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations","volume":"14","author":"Stein GL","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1684\/ejd.2014.2293","article-title":"Efficacy and safety of clindamycin phosphate 1.2%\/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double\u2010blind, parallel\u2010group, phase III studies","volume":"24","author":"Dreno B","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_26_1","first-page":"256","article-title":"Tazarotene versus tazarotene plus clindamycin\/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double\u2010blind, randomized parallel\u2010group trial","volume":"5","author":"Tanghetti E","year":"2006","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.12497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:22:14Z","timestamp":1695572534000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.12497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/jocd.12497"],"URL":"https:\/\/doi.org\/10.1111\/jocd.12497","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}